Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience
| Autor: | Alain Fourquet, B. De Lafontan, Frédérique Penault-Llorca, Bruno Cutuli, Sylvie Lancrenon, R. Pioud-Martigny, C. Tunon de Lara, François Campana, S. Giard, E Mery, Hugo Marsiglia, A. Meunier, Claire Lemanski, Eric Fondrinier |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty medicine.medical_treatment Breast Neoplasms Mastectomy Segmental Breast cancer ductal carcinoma in situ Clinical Studies medicine Breast-conserving surgery Humans breast carcinoma Prospective Studies radiotherapy Aged Aged 80 and over tamoxifen business.industry Carcinoma in situ mastectomy Sentinel node Ductal carcinoma Middle Aged medicine.disease Combined Modality Therapy Surgery Radiation therapy Carcinoma Intraductal Noninfiltrating Cross-Sectional Studies Oncology Female Radiotherapy Adjuvant Radiology breast-conserving surgery Breast carcinoma business Mastectomy Mammography |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | From March 2003 to April 2004, 77 physicians throughout France prospectively recruited 1289 ductal carcinoma in situ (DCIS) patients and collected data on diagnosis, patient and tumour characteristics, and treatments. Median age was 56 years (range, 30–84). Ductal carcinoma in situ was diagnosed by mammography in 87.6% of patients. Mastectomy, conservative surgery alone (CS) and CS with radiotherapy (CS+RT) were performed in 30.5, 7.8 and 61.7% of patients, respectively. Thus, 89% of patients treated by CS received adjuvant RT. Sentinel node biopsy (SNB) and axillary dissection (AD) were performed in 21.3 and 10.4% of patients, respectively. Hormone therapy was administered to 13.4% of the patients (80% tamoxifen). Median tumour size was 14.5 mm (6, 11 and 35 mm for CS, CS+RT and mastectomy, respectively, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|